Krystal Biotech (KRYS) Work In Process (2023 - 2026)

Krystal Biotech has reported Work In Process for 4 years, with the latest figure at $20.9 million in Q2 2026.

• Work In Process for Q2 2026 came in at $20.9 million, up 36.98% year-over-year; the trailing twelve-month figure through Jun 2026 was $20.9 million (up 36.98% YoY), and the FY2025 annual result was $15.2 million, up 41.71% from the prior year.
• Work In Process improved to $20.9 million in Q2 2026, from $15.1 million in the prior quarter.
• Over five years, Work In Process peaked at $20.9 million in Q2 2026 and troughed at $3.2 million in Q4 2023.
• A 4-year average of $11.2 million and a median of $10.7 million in 2024 frame the typical range for Work In Process.
• The widest annual swing landed in 2024, when Work In Process surged 235.3%; it then soared 36.98% in 2026.
• A 4-year view of Work In Process shows it stood at $3.2 million in 2023, then surged by 235.3% to $10.7 million in 2024, then soared by 41.71% to $15.2 million in 2025, then soared by 37.53% to $20.9 million in 2026.
• Per Business Quant data, the three most recent Work In Process figures were $20.9 million in Q2 2026, $15.1 million in Q1 2026, and $15.2 million in Q4 2025.